Clinigen Group plc (the "Company", AIM: CLIN) announces that it has made an application for the admission to trading on AIM of 5,011 ordinary shares of 0.1 pence each in the Company (the "New Ordinary Shares"), which have been issued to satisfy the exercise of share options and rank pari passu with the existing shares of the Company. Admission to trading on AIM of the New Ordinary Shares is anticipated to occur on 23 March 2016.
At admission the issued share capital of the Company will consist of 114,565,213 ordinary shares, with no shares held in treasury. The total number of voting rights in the Company will therefore be 114,565,213. This figure may be used by shareholders as the denominator to determine if they are required to notify their interests in, or a change to their interest in, the Company under the Disclosure and Transparency Rules.
Clinigen Group plc
Peter George, Group Chief Executive Officer
Shaun Chilton, Group Deputy Chief Executive Officer
Martin Abell, Group Chief Financial Officer
Tel: +44 (0) 1283 495010
Numis Securities Limited
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard (Corporate Broking)
Tel: +44 (0) 20 7260 1000
Peel Hunt LLP - Joint Broker
James Steel/Dr. Tom Burt
Tel: +44 (0) 20 7418 8900
Adrian Duffield/Melanie Toyne-Sewell/Jayne Crook
Tel: +44 (0) 20 7457 2020
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right drug to the right patient at the right time.
The Group consists of five synergistic businesses focused in three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in the management and supply of commercial medicines for clinical trials.
The Group is also the trusted global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, through three of its divisions: Idis Managed Access runs early access programs for innovative new medicines. Idis Global Access and Link Healthcare work directly with healthcare professionals to enable compliant access to unlicensed medicines on a global basis and niche essential licensed and generic medicines across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights, revitalises and markets its own portfolio of niche hospital commercial products.
For more information, please visit www.clinigengroup.com